TrialAnnals of the rheumatic diseases2018

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Cem Gabay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.